Overview

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Status:
Completed

Trial end date:
2016-05-31

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.

Phase:

Phase 1

Details

Lead Sponsor:

Alios Biopharma Inc.

Treatments:

Adafosbuvir